DOV Initiates Second Bicifadine Phase III Trial In Revamped Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DOV Pharmaceuticals' second Phase III clinical trial for its chronic lower back pain agent bicifadine will enroll a limited patient population, the company announced May 22